SavedAdd your journal

Journals / ANKEM Dergisi / 2004 / Cilt: 18 - Sayı: 2

In vitro activity of antibiotics with beta-lactamase inhibitors against extended-spectrum beta-lactamase producing blood isolates of Klebsiella strains

Genişlemiş spektrumlu beta-laktamaz üreten kan izolatı Klebsiella suşlarına karşı beta-laktamaz inhibitörlü antibiyotiklerin in-vitro etkinliği

Yusuf YAKUPOĞULLARI
Aşçı Zülal TORAMAN
Ahmet KİZİRGİL
Pages
109–112
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This shows that betalactam and beta-lactamase inhibitor combinations can be used rarely in life threatening conditions, such as blood stream infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In vitro activity of piperacillin-tazobactam, cefoperazone-sulbactam, ticarcillin-clavulanate, amoxicillin-clavulanate and ampicillin-sulbactam were investigated with E-test in blood isolates of extended-spectrum beta-lactamase producing Klebsiella strains.
📊
Key Findings & Data:Of the total 56 Klebsiella pneumoniae and 21 Klebsiella oxytoca, extended-spectrum beta-lactamase was detected in 35 (62.5 %) K.pneumoniae and nine (43 %) K.oxytoca strains by double disk synergy test.
💡
Conclusion & Impact:This shows that betalactam and beta-lactamase inhibitor combinations can be used rarely in life threatening conditions, such as blood stream infections.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Anti-bakteriyel ajanlar · beta-Laktamazlar · Kan

Abstract

In vitro activity of piperacillin-tazobactam, cefoperazone-sulbactam, ticarcillin-clavulanate, amoxicillin-clavulanate and ampicillin-sulbactam were investigated with E-test in blood isolates of extended-spectrum beta-lactamase producing Klebsiella strains. Of the total 56 Klebsiella pneumoniae and 21 Klebsiella oxytoca, extended-spectrum beta-lactamase was detected in 35 (62.5 %) K.pneumoniae and nine (43 %) K.oxytoca strains by double disk synergy test. Of the extendedspectrum beta-lactamase producing strains, 21 (48 %) were found as susceptible to piperacillin-tazobactam, 20 (45 %) to cefoperazone-sulbactam, five (11 %) to ticarcillin-clavulanate, five (11 %) to amoxicillin-clavulanate and three (7 %) to ampicillin-sulbactam. Although, there were relatively higher susceptibility to piperacillin-tazobactam and cefoperazonesulbactam than other combinations, the efficacy ratios were low even for these two combinations. This shows that betalactam and beta-lactamase inhibitor combinations can be used rarely in life threatening conditions, such as blood stream infections.

Özet

Kan kültürlerinden soyutlanan genişlemiş spektrumlu beta-laktamaz üreten Klebsiella suşlarında piperasilin-tazobaktam, sefoperazon-sulbaktam, tikarsilin-klavulanat, amoksisilin-klavulanat ve ampisilin-sulbaktamın in-vitro etkinliği E-test ile araştırılmıştır. 56 Klebsiella pneumoniae suşunun 35’inde (% 62.5) ve 21 Klebsiella oxytoca suşunun dokuzunda (% 43) çift disk sinerji yöntemi ile genişlemiş spektrumlu beta-laktamaz saptanmıştır. Genişlemiş spektrumlu beta-laktamaz üreten bu suşların 21’i (% 48) piperasilin-tazobaktama, 20’si (% 45) sefoperazon-sulbaktama, beşi (% 11) tikarsilin-klavulanata, beşi (% 11) amoksisilin-klavulanata ve üçü (% 7) ampisilin-sulbaktama duyarlı bulunmuştur. Çalışılan antibiyotikler içinde, piperasilin-tazobaktam ve sefoperazon-sulbaktam duyarlılığı göreceli olarak daha yüksek olmakla birlikte, kan dolaşımı infeksiyonları gibi hayatı tehdit eden durumlarda, beta-laktamaz inhibitörlü antibiyotiklerin ancak çok az sayıdaki duyarlı suşlarda kullanılabileceği sonucuna ulaşılmıştır.

🔖

Cite This Article

YAKUPOĞULLARI, Y., TORAMAN, A. Z., KİZİRGİL, A. (2004). In vitro activity of antibiotics with beta-lactamase inhibitors against extended-spectrum beta-lactamase producing blood isolates of Klebsiella strains. ANKEM Dergisi, Cilt: 18 - Sayı: 2, 109–112. https://ajindex.com/articles/211783

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. AmbrosePG,BhavnaniSM,JonesRN: Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended spectrum betalactamases: report from the ARREST program, Antimicrob Agents Chemother 2003
  2. Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE: Clinical and microbiologic analysis of a hospital’s extended spectrum betalactamase- producing isolates over a 2-year period, Pharmacotherapy 2003
  3. Gioia SB, Livermore DM: Antimicrobial resistance among Klebsiella spp. collected from intensive care units in southern and western Europe in 1997-98, J Antimicrob Chemother 2000
  4. Gioia SB, Yuan M, Hall LMC, Livermore DM: Variable susceptibility to piperacillin-tazobactamamongst Klebsiella spp.with extended spectrum beta-lactamases, J Antimicrob Chemother 2003
  5. Gulay Z,Thomson CJ,YulugN,Amyes SG:High prevalence of extendedspectrum beta-lactamase production among Klebsiella pneumoniae strains isolated at a university hospital in Turkey, J Chemother 2000
  6. Kim YK, Pai H, Lee HJ et al: Bloodstream infections by extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome,Antimicrob Agents Chemother 2002
  7. Lautenbach E, Patel JB, BilkerWB, Edelstein PH, Fishman NO: Extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes, Clin Infect Dis 2001
  8. Leleu G, Kitzis MD, Vallois JM, Gutman L, Decazes JM: Different ratios of the piperacillin-tazobactam combination for the treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrumbeta-lactamases,AntimicrobAgents Chemother 1994
  9. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests, M2 A6, Vol 17, No:1, National Committee for Clinical Laboratory Standards,Villanova (1997). 10. Patersson DL: Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrumbeta-lactamases (ESBLs), Clin Microbiol Infect 2000
  10. Patersson DL, Ko WC, Gottberg AV et al: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, J Clin